WO2023192639A3 - Combination immunotherapy - Google Patents

Combination immunotherapy Download PDF

Info

Publication number
WO2023192639A3
WO2023192639A3 PCT/US2023/017196 US2023017196W WO2023192639A3 WO 2023192639 A3 WO2023192639 A3 WO 2023192639A3 US 2023017196 W US2023017196 W US 2023017196W WO 2023192639 A3 WO2023192639 A3 WO 2023192639A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
combination immunotherapy
ligands
administering
soluble
Prior art date
Application number
PCT/US2023/017196
Other languages
French (fr)
Other versions
WO2023192639A2 (en
Inventor
Kellie N. SMITH
Drew M. Pardoll
Justina CAUSHI
Jiajia Zhang
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of WO2023192639A2 publication Critical patent/WO2023192639A2/en
Publication of WO2023192639A3 publication Critical patent/WO2023192639A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

In one aspect, methods of treating cancer are provided that comprise: administering to a subject a composition comprising a therapeutically effective amount of: a first agent which inhibits programmed death 1 (PD-1) expression or function, or antagonizes binding to ligands thereof, and a second agent comprising at least one of: a checkpoint antagonist, an IL-7 receptor agonist or soluble IL-7.
PCT/US2023/017196 2022-03-31 2023-03-31 Combination immunotherapy WO2023192639A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263326221P 2022-03-31 2022-03-31
US63/326,221 2022-03-31

Publications (2)

Publication Number Publication Date
WO2023192639A2 WO2023192639A2 (en) 2023-10-05
WO2023192639A3 true WO2023192639A3 (en) 2023-11-09

Family

ID=88203355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/017196 WO2023192639A2 (en) 2022-03-31 2023-03-31 Combination immunotherapy

Country Status (1)

Country Link
WO (1) WO2023192639A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177179A1 (en) * 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
US20210252122A1 (en) * 2019-12-03 2021-08-19 Neuvogen, Inc. Tumor cell vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177179A1 (en) * 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2020163876A1 (en) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions and methods involving layilin
US20210252122A1 (en) * 2019-12-03 2021-08-19 Neuvogen, Inc. Tumor cell vaccines

Also Published As

Publication number Publication date
WO2023192639A2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
Aglietta et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
Zatloukal et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Duffy et al. Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer
Hu et al. Emerging therapies for breast cancer
Nemunaitis et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
Queirolo et al. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Zammarchi et al. CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
JP2020040992A (en) Methods for treating neuroendocrine tumors that overexpress somatostatin receptors
WO2008091641A3 (en) Compositions and methods for diagnosing and treating cancer
Tomek et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments
NZ569428A (en) Treatment of conditions involving demyelination with a Sp35 antagonist
Paz-Ares et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
WO2008010101A3 (en) Antagonist antibody against epha2 for the treatment of cancer
Gentile et al. Bendamustine in multiple myeloma
Zhan et al. Autophagy therapeutics: preclinical basis and initial clinical studies
Perini et al. Brentuximab vedotin in CD30+ lymphomas
BR112020009363A2 (en) methods and compositions to treat cancer by modifying multiple arms of the immune system
Rauschenberg et al. Systemic therapy of metastatic melanoma
Campone et al. A three‐arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines
Page et al. Checkpoint modulation in melanoma: an update on ipilimumab and future directions
Criscitiello et al. Targeted therapies in breast cancer: are heart and vessels also being targeted?
WO2023192639A3 (en) Combination immunotherapy
Toulmonde et al. Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study
Rocca et al. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
WO2021158091A3 (en) Composition comprising chemokine inhibitor, colony stimulating factor inhibitor, and cancer immunotherapy agent for prevention or treatment of cancer and combination therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23781905

Country of ref document: EP

Kind code of ref document: A2